# National Taiwan University of Science and Technology

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-taiwan-university-of-science-and-technology/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 98.6 |
| Citations | 1,952,664 |
| City | Taipei |
| Country | TW |
| Description | National Taiwan University of Science and Technology is a research organisation in Taipei, TW. OpenAlex records 39,214 works and 1,952,664 citations for it. 12,749 researchers list it as their most recent affiliation. |
| Homepage | http://www.ntust.edu.tw/home.php?Lang=en |
| OpenAlex ID | https://openalex.org/I154864474 |
| Region | Taipei |
| Researchers | 12,749 |
| ROR ID | https://ror.org/00q09pe49 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q699543 |
| Works | 39,214 |

## University papers

- [Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study](https://scholariq.org/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/)
- [Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study](https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/)
- [Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma](https://scholariq.org/papers/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/)
- [Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/durvalumab-with-or-without-bevacizumab-with-transarterial-chemoembolisation-in/)
- [Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO](https://scholariq.org/papers/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-2/)

## University top topics

Showing 8 of 25.

- [Advancements in Battery Materials](https://scholariq.org/topics/advancements-in-battery-materials/)
- [Advanced Photocatalysis Techniques](https://scholariq.org/topics/advanced-photocatalysis-techniques/)
- [Conducting polymers and applications](https://scholariq.org/topics/conducting-polymers-and-applications/)
- [Advanced Battery Technologies Research](https://scholariq.org/topics/advanced-battery-technologies-research/)
- [Advanced Battery Materials and Technologies](https://scholariq.org/topics/advanced-battery-materials-and-technologies/)
- [Radio Frequency Integrated Circuit Design](https://scholariq.org/topics/radio-frequency-integrated-circuit-design/)
- [Electrocatalysts for Energy Conversion](https://scholariq.org/topics/electrocatalysts-for-energy-conversion/)
- [Microwave Engineering and Waveguides](https://scholariq.org/topics/microwave-engineering-and-waveguides/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.